Keynote Presentation: Immunogenomic Characterization of Tumor-Reactive TIL in Lung Cancers скачать в хорошем качестве

Keynote Presentation: Immunogenomic Characterization of Tumor-Reactive TIL in Lung Cancers

Presented By: Kellie Smith, PhD Speaker Biography: Kellie N. Smith, Ph.D., is an Associate Professor of Oncology in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins School of Medicine. Dr. Smith, a Baltimore, MD native, completed her doctoral work at the University of Pittsburgh School of Medicine under the direction of Dr. Charles R. Rinaldo with a focus on T cell immunology and immunotherapy. During her fellowship training at Johns Hopkins, she worked under the mentorship of Dr. Drew M. Pardoll identifying the correlates of response to anti-PD-1 immunotherapy in patients with multiple tumor histologies with a specific emphasis on early and advanced stage non-small cell lung cancer. She joined the faculty in early 2016 and has since collaborated with many clinicians within Johns Hopkins and at outside institutions on immunotherapy clinical trials aimed at improving treatment options, preventing disease recurrence, and understanding the predictors of response to treatment in both early and advanced stage disease. Dr. Smith's group has long focused on integrating multi-omics technologies to study tumor-reactive T cells in the setting of various cancer types, with a specific focus on lung cancer. Her lab showed for the first time that neoantigen-specific T cells are amplified in the periphery following neoadjuvant PD-1 blockade and that these responses may facilitate tumor regression and prevent relapse after surgical resection. Her work in the setting of resectable lung cancer has identified several molecules and pathways associated with checkpoint blockade response/resistance that are being investigated for therapeutic targeting. A current focus... Webinar: Keynote Presentation: Immunogenomic Characterization of Tumor-Reactive TIL in Lung Cancers w/ Live Q&A Webinar Abstract: Non-small cell lung cancer (NSCLC) accounts for more deaths than colon, breast, and prostate cancers combined. Of patients with NSCLC, 20% initially present with stage I or II disease, for which neoadjuvant PD-1 blockade combined with chemotherapy is now the standard of care. The success of PD-1 blockade is predicated on the fact that a critical end-effector of anti-tumor immunity is the T cell. We and others have demonstrated the role of CD4+ (helper) and CD8+ (effector) T cells targeting epitopes derived from tumor somatic mutations (neoantigens) in response to anti-PD-1 in metastatic NSCLC. Additionally, many groups have examined intratumoral characteristics of T cells at the single cell level in human cancers, but these studies suffer from a fundamental limitation: they cannot distinguish true tumor-specific T cells from T cells with irrelevant antigen specificity. In this presentation, I will demonstrate how our lab is developing innovative methods to better detect and study tumor-reactive TIL in the context of resectable lung cancers. Earn PACE Credits: 1. Make sure you’re a registered member of Labroots (https://www.labroots.com/) 2. Watch the webinar on YouTube or on the Labroots Website (https://www.labroots.com/ms/webinar/k...) 3. Click Here to get your PACE credits (Expiration date – April 30, 2027): (https://www.labroots.com/credit/pace-...) Labroots on Social: Facebook:   / labrootsinc   Twitter:   / labroots   LinkedIn:   / labroots   Instagram:   / labrootsinc   Pinterest:   / labroots   SnapChat: labroots_inc